| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Galera Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 64,000 | 14 Jun 2023 | Direct | ||
| Bicara Therapeutics Inc. | Director | Stock Option (Right to Buy) | 23,746 | 09 Jun 2025 | Direct | ||
| Checkmate Pharmaceuticals, Inc. | Director | Stock Option (Right to Buy) | 0 | 31 May 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 09 Jun 2025 | 1 | $0 | 4 | Director | 10 Jun 2025, 16:30 |
| BCAX | Bicara Therapeutics Inc. | 12 Sep 2024 | 0 | $0 | 3 | Director | 12 Sep 2024, 21:16 |
| GRTX | Galera Therapeutics, Inc. | 14 Jun 2023 | 1 | $0 | 4 | Director | 16 Jun 2023, 16:15 |
| GRTX | Galera Therapeutics, Inc. | 15 Jun 2022 | 1 | $0 | 4 | Director | 16 Jun 2022, 16:05 |
| CMPI | Checkmate Pharmaceuticals, Inc. | 31 May 2022 | 3 | $0 | 4 | Director | 31 May 2022, 10:14 |
| CMPI | Checkmate Pharmaceuticals, Inc. | 09 Aug 2021 | 1 | $0 | 4 | Director | 10 Aug 2021, 16:05 |
| CMPI | Checkmate Pharmaceuticals, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 21 Jun 2021, 21:18 |
| GRTX | Galera Therapeutics, Inc. | 16 Jun 2021 | 1 | $0 | 4 | Director | 17 Jun 2021, 18:39 |